Ascendis Pharma A/S Stock price

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2023-09-29 pm EDT Intraday chart for Ascendis Pharma A/S 5-day change 1st Jan Change
93.64 USD -1.38% -1.49% -23.33%
Sales 2023 * 214 M 227 M Sales 2024 * 356 M 377 M Capitalization 5 052 M 5 356 M
Net income 2023 * -520 M -551 M Net income 2024 * -464 M -492 M EV / Sales 2023 *
24,3x
Net Debt 2023 * 150 M 159 M Net Debt 2024 * 241 M 256 M EV / Sales 2024 *
14,9x
P/E ratio 2023 *
-9,83x
P/E ratio 2024 *
-11,5x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float10.27%
More Fundamentals * Assessed data
Dynamic Chart
Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency CI
Pharma Stocks Lead European Equities Traded in the US as American Depositary Receipts Lower Thursday MT
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading MT
Ascendis Pharma Launches Skytrofa Growth Hormone in Germany MT
Constellation Software's Perseus Closes Purchase of Black Knight's Empower, Optimal Blue Businesses MT
Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency CI
Ascendis Pharma's TransCon PTH Receives Positive Opinion From European Regulator MT
Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism CI
European Equities Traded in the US as American Depositary Receipts Slightly Higher Wednesday MT
Transcript : Ascendis Pharma A/S Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 12:55 PM CI
Prime Mining Corp. Announcing Expansion Drilling Results From the Z-T, Guadalupe and Central Zones at Los Reyes MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher Monday MT
Transcript : Ascendis Pharma A/S Presents at Citi 18th Annual BioPharma Conference, Sep-07-2023 02:40 PM CI
European Equities Traded in the US as American Depositary Receipts Trend Lower Wednesday MT
Morgan Stanley Adjusts Price Target on Ascendis Pharma to $113 From $109, Maintains Equalweight Rating MT
More news
1 day+0.42%
1 week-0.51%
Current month-3.13%
1 month-3.57%
3 months+9.16%
6 months-13.46%
Current year-22.25%
More quotes
1 week
91.59
Extreme 91.585
96.68
1 month
91.59
Extreme 91.585
106.45
Current year
64.33
Extreme 64.33
127.77
1 year
64.33
Extreme 64.33
134.53
3 years
61.58
Extreme 61.5791
183.98
5 years
53.21
Extreme 53.205
183.98
10 years
11.92
Extreme 11.92
183.98
More quotes
Date Price Change Volume
23-09-29 93.64 -1.38% 235 983
23-09-28 94.95 +0.94% 205,004
23-09-27 94.07 -0.15% 197,508
23-09-26 94.21 -1.35% 331,333
23-09-25 95.50 +0.46% 180,510

Delayed Quote Nasdaq, September 28, 2023 at 04:00 pm EDT

More quotes
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
89.86EUR
Average target price
132.91EUR
Spread / Average Target
+47.91%
Consensus
  1. Markets
  2. Equities
  3. Stock Ascendis Pharma A/S - Nasdaq
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer